Comparison of antiviral resistance across acute and chronic viral infections

Stephen Mason, John Devincenzo, Stephen Toovey, Jim Z. Wu, Richard J. Whitley

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Antiviral therapy can lead to drug resistance, but multiple factors determine the frequency of drug resistance mutations and the clinical consequences. When chronic infections caused by Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) are compared with acute infections such as influenza virus, respiratory syncytial virus (RSV), and other respiratory viruses, there are similarities in how and why antiviral resistance substitutions occur, but the clinical significance can be quite different. Emergence of resistant variants has implications for design of new therapeutics, treatment guidelines, clinical trial design, resistance monitoring, reporting, and interpretation. In this discussion paper, we consider the molecular factors contributing to antiviral drug resistance substitutions, and a comparison is made between chronic and acute infections. The implications of resistance are considered for clinical trial endpoints and public health, as well as the requirements for therapeutic monitoring in clinical practice with acute viral infections.

Original languageEnglish (US)
Pages (from-to)103-112
Number of pages10
JournalAntiviral Research
Volume158
DOIs
StatePublished - Oct 1 2018

Fingerprint

Virus Diseases
Antiviral Agents
Drug Resistance
Viral Drug Resistance
Infection
Clinical Trials
Drug Substitution
Respiratory Syncytial Viruses
R Factors
Therapeutics
Orthomyxoviridae
Hepatitis B virus
Hepacivirus
Public Health
HIV
Guidelines
Viruses
Mutation

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Virology

Cite this

Comparison of antiviral resistance across acute and chronic viral infections. / Mason, Stephen; Devincenzo, John; Toovey, Stephen; Wu, Jim Z.; Whitley, Richard J.

In: Antiviral Research, Vol. 158, 01.10.2018, p. 103-112.

Research output: Contribution to journalReview article

Mason, Stephen ; Devincenzo, John ; Toovey, Stephen ; Wu, Jim Z. ; Whitley, Richard J. / Comparison of antiviral resistance across acute and chronic viral infections. In: Antiviral Research. 2018 ; Vol. 158. pp. 103-112.
@article{238b305412614cd692663d45a2346f1f,
title = "Comparison of antiviral resistance across acute and chronic viral infections",
abstract = "Antiviral therapy can lead to drug resistance, but multiple factors determine the frequency of drug resistance mutations and the clinical consequences. When chronic infections caused by Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) are compared with acute infections such as influenza virus, respiratory syncytial virus (RSV), and other respiratory viruses, there are similarities in how and why antiviral resistance substitutions occur, but the clinical significance can be quite different. Emergence of resistant variants has implications for design of new therapeutics, treatment guidelines, clinical trial design, resistance monitoring, reporting, and interpretation. In this discussion paper, we consider the molecular factors contributing to antiviral drug resistance substitutions, and a comparison is made between chronic and acute infections. The implications of resistance are considered for clinical trial endpoints and public health, as well as the requirements for therapeutic monitoring in clinical practice with acute viral infections.",
author = "Stephen Mason and John Devincenzo and Stephen Toovey and Wu, {Jim Z.} and Whitley, {Richard J.}",
year = "2018",
month = "10",
day = "1",
doi = "10.1016/j.antiviral.2018.07.020",
language = "English (US)",
volume = "158",
pages = "103--112",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",

}

TY - JOUR

T1 - Comparison of antiviral resistance across acute and chronic viral infections

AU - Mason, Stephen

AU - Devincenzo, John

AU - Toovey, Stephen

AU - Wu, Jim Z.

AU - Whitley, Richard J.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Antiviral therapy can lead to drug resistance, but multiple factors determine the frequency of drug resistance mutations and the clinical consequences. When chronic infections caused by Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) are compared with acute infections such as influenza virus, respiratory syncytial virus (RSV), and other respiratory viruses, there are similarities in how and why antiviral resistance substitutions occur, but the clinical significance can be quite different. Emergence of resistant variants has implications for design of new therapeutics, treatment guidelines, clinical trial design, resistance monitoring, reporting, and interpretation. In this discussion paper, we consider the molecular factors contributing to antiviral drug resistance substitutions, and a comparison is made between chronic and acute infections. The implications of resistance are considered for clinical trial endpoints and public health, as well as the requirements for therapeutic monitoring in clinical practice with acute viral infections.

AB - Antiviral therapy can lead to drug resistance, but multiple factors determine the frequency of drug resistance mutations and the clinical consequences. When chronic infections caused by Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) are compared with acute infections such as influenza virus, respiratory syncytial virus (RSV), and other respiratory viruses, there are similarities in how and why antiviral resistance substitutions occur, but the clinical significance can be quite different. Emergence of resistant variants has implications for design of new therapeutics, treatment guidelines, clinical trial design, resistance monitoring, reporting, and interpretation. In this discussion paper, we consider the molecular factors contributing to antiviral drug resistance substitutions, and a comparison is made between chronic and acute infections. The implications of resistance are considered for clinical trial endpoints and public health, as well as the requirements for therapeutic monitoring in clinical practice with acute viral infections.

UR - http://www.scopus.com/inward/record.url?scp=85051369001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051369001&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2018.07.020

DO - 10.1016/j.antiviral.2018.07.020

M3 - Review article

VL - 158

SP - 103

EP - 112

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

ER -